Mgr. Michal Šmída, Dr. rer. nat.
Research Group Leader Junior, Michal Šmída Research Group
office: bldg. E35/186
Kamenice 753/5
625 00 Brno
phone: | +420 532 23 5494 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 78
2023
-
Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation in rituximab-resistant cells.
Year: 2023, type: Conference abstract
-
Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation.
Year: 2023, type: Conference abstract
-
Chasing the epigenetic landscape to enhance CAR-T cell activity py preventing CD19 antigen escape in relapsed models.
Year: 2023, type: Conference abstract
-
Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening.
Year: 2023, type: Conference abstract
-
Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.
Year: 2023, type: Conference abstract
-
Nově identifikovaná varianta v genu CYCS u rodiny s trombocytopenií typu 4 a její funkční dopad.
Year: 2023, type: Conference abstract
-
Varianta v genu CYCS způsobující trombocytopenii 4 zvyšuje kaspázovou aktivitu.
Year: 2023, type: Conference abstract
2022
-
. Drug repurposing for venetoclax-resistant acute myeloid leukemia.
Year: 2022, type: Conference abstract
-
A GP1BA Variant in a Czech Family with Monoallelic Bernard-Soulier Syndrome
International Journal of Molecular Sciences, year: 2022, volume: 23, edition: 2, DOI
-
Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells.
Year: 2022, type: Conference abstract